Abstract
The pre-treatment serum levels of carbohydrate antigen 125 (CA125), cytokeratin 19 fragment 21-1 (CYFRA21-1), squamous carcinoma associated antigen (SCC-Ag), and tissue polypeptide antigen (TPA) were measured in 111 patients with primary non-small-cell lung cancer. And 103 benign lung disease cases and 97 healthy volunteers were also studied as controls. Enzyme linked immunosorbent assay (ELISA) was employed to detect the serum contents of SCC-Ag and TPA. The levels of CA125 and CYFRA21-1 were measured by electrochemical luminescence. The serum level of CYFRA21-1, SCC, TPA and CA125 in cancer patients were significantly higher than those of normal control and benign disease groups (P<0.01). The combined detection of tumor markers could significantly improve the sensitivity and specificity. And the levels of tumor markers were also correlated with the clinical stages and differentiation degrees. Key words: Carcinoma，non-small-cell lung; Early diagnosis
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
